Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment
- 10 April 2020
- journal article
- editorial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 75 (20), 2623-2624
- https://doi.org/10.1016/j.jacc.2020.04.016
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to HydroxychloroquineCase Reports in Cardiology, 2016
- Hydroxychloroquine reduces heart rate by modulating the hyperpolarization-activated current If: Novel electrophysiological insights and therapeutic potentialHeart Rhythm, 2015
- Assessment of temperature‐induced hERG channel blockade variation by drugsJournal of Applied Toxicology, 2014
- Suspected Hydroxychloroquine-Associated QT-Interval Prolongation in a Patient With Systemic Lupus ErythematosusJCR: Journal of Clinical Rheumatology, 2013
- Cardiovascular Risks with Azithromycin and Other Antibacterial DrugsNew England Journal of Medicine, 2013
- Azithromycin and the Risk of Cardiovascular DeathNew England Journal of Medicine, 2012
- Azithromycin‐Induced Torsade De PointesPacing and Clinical Electrophysiology, 2007
- Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factorsJournal of Interventional Cardiac Electrophysiology, 2007
- Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular ArrhythmiaClinical Toxicology, 2006
- Polymorphic Ventricular Tachycardia with a Normal QT Interval Following AzithromycinPacing and Clinical Electrophysiology, 2005